NASDAQ · TRML
Tourmaline Bio, Inc.
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
Loading market information…
NASDAQ · JNCE · USD
Stock price, earnings
Quote as of May 3, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Jounce Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.99% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jounce Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Jounce Therapeutics, Inc. is an immunotherapy firm currently in the clinical development phase, dedicated to discovering and advancing new cancer treatments. A key asset in its pipeline is vopratelimab, a monoclonal antibody presently in Phase II clinical trials. This therapeutic agent functions by binding to and activating the Inducible T cell CO-Stimulator (ICOS), a specific protein located on the surface of T cells within various solid tumors. The company is also progressing JTX-8064, an antibody designed to target leukocyte immunoglobulin like receptor B2 (LILRB2), a cell surface receptor found on macrophages. Additionally, JTX-1484 is under development, focusing on myeloid targets. Completing its innovative portfolio is JTX-1811, an anti-CCR8 monoclonal antibody precisely engineered to selectively reduce the presence of intra-tumoral T regulatory cells within the tumor's microenvironment. Jounce Therapeutics, Inc. was founded in 2012 and maintains its primary operational base in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:28 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00-100.0% vs estimate |
| Q2 2021 | Aug 5, 2021 | -$0.08+78.95% vs estimate | $25.37M+210.12% vs estimate |
|---|
KEEP COMPARING
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
$4.91-$0.04 (-0.81%)
Decibel Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.07% below the high.
$20.65$0.00 (0.0%)
Opiant Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.52% below the high.
$3.02-$0.07 (-2.27%)
Cyteir Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.33% below the high.
$2.09-$0.01 (-0.48%)
HilleVax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.69% below the high.
$3.01-$0.17 (-5.35%)
Insight Molecular Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.63% below the high.
$2.05-$0.05 (-2.38%)
Aadi Bioscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.22% below the high.
$3.39+$0.02 (+0.59%)
Miromatrix Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.07% below the high.
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
| -83.87M |
| -1.82 |
| -337.73% |
| FY 2020 | 62.34M | -43.84M | -27.88M | -1.24 | -70.33% |
|---|
| FY 2019 | 147.87M | 56.82M | -31.11M | 1.72 | 38.43% |
|---|
| FY 2018 | 65.2M | -27.38M | -64.97M | -0.84 | -41.99% |
|---|
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
